AIDS Healthcare Foundation, Miami, FL, USA.
Epividian, Inc, Raleigh, NC, USA.
J Int Assoc Provid AIDS Care. 2024 Jan-Dec;23:23259582241245223. doi: 10.1177/23259582241245223.
We evaluated the impact of the CHORUS™ app on adherence to the cabotegravir and rilpivirine long-acting injectable (CAB + RPV LAI) monthly injections schedule.
Healthcare centers (HCCs) were randomized to access CHORUS™ CAB + RPV LAI features (intervention) or not (control) from 01OCT2021-31JAN2022. Target window adherence (maintenance injections ≤7 days before/after target day) was assessed with multivariate logistic regression (generalized estimating equations).
CAB + RPV LAI was administered to 188 and 79 individuals at intervention and control HCCs, respectively. Intervention was not associated with improved target window adherence (adjusted odds ratio: 0.61 [95% CI: 0.30-1.25]). However, app use was associated with increased odds of adherence compared to no app use among all intervention HCCs (2.98 [1.26-7.06]) and at smaller HCCs (3.58 [1.31-9.80]).
While access to CHORUS™ CAB + RPV LAI features did not improve target window adherence, app use did, especially at smaller HCCs which may not have established LAI management procedures.
我们评估了 CHORUS™ 应用程序对卡替拉韦和利匹韦林长效注射剂（CAB+RPV LAI）每月注射方案依从性的影响。
从 2021 年 10 月 1 日至 2022 年 1 月 31 日，医疗中心（HCC）被随机分配以访问 CHORUS™ CAB+RPV LAI 功能（干预组）或不访问（对照组）。采用多变量逻辑回归（广义估计方程）评估目标窗口依从性（维持注射在目标日前后≤7 天）。
干预组和对照组 HCC 分别为 188 人和 79 人接受了 CAB+RPV LAI 治疗。干预组与目标窗口依从性的改善无关（调整后的优势比：0.61 [95%CI：0.30-1.25]）。然而，与没有使用应用程序相比，在所有干预 HCC 中，使用应用程序与更高的依从性几率相关（2.98 [1.26-7.06]），在较小的 HCC 中则更高（3.58 [1.31-9.80]）。
尽管可以访问 CHORUS™ CAB+RPV LAI 功能，但并不能提高目标窗口的依从性，而应用程序的使用确实可以提高依从性，尤其是在尚未建立 LAI 管理程序的较小 HCC 中。
